Newsletters

10.01.24

CA Climate Disclosure Mandates—Deadlines Hold and the Clock is Ticking

Even California’s “Climate Governor” had concerns about rushing hastily into California’s unprecedented climate disclosure mandate laws.


09.27.24

DOJ Repeals 1995 Bank Merger Guidelines and Now Will Apply Its 2023 Merger Guidelines to Bank M&A

On September 17, 2024, the Antitrust Division of the United States Department of Justice (the “DOJ”) announced that it withdrew its 1995 Bank Merger Guidelines and instead, for purposes of evaluating the competitive impact of bank mergers, will rely on its 2023 Merger Guidelines, which ...


09.26.24

Washington PDAB Chooses Selection Methodology for Identifying Eligible Drugs Washington PDAB Chooses

On Wednesday, September 18, Washington’s Prescription Drug Affordability Board (PDAB) finalized its methodology for selecting drugs for affordability reviews.


09.26.24

HRSA Threatens to Sanction J&J Absent Withdrawal of 340B Rebate Plan

On September 17, the Health Resources and Services Administration (HRSA), which administers the prescription drug discount program established under Section 340B of the federal Public Health Service Act, sent a letter to pharmaceutical manufacturer Johnson & Johnson (J&J), threatening to ...


09.26.24

House E&C Advances Telehealth Extension

On September 18, the House Energy and Commerce (E&C) Committee held a full committee markup and advanced 16 bills.


09.26.24

FTC Sues PBMs Over Insulin Pricing, While Express Scripts Sues Commission Over PBM Interim Report

On September 20, the Federal Trade Commission (FTC) filed its first administrative complaint against PBMs under Chair Lina Khan, alleging "anticompetitive and unfair rebating practices” by the three largest PBMs that have inflated insulin prices.


09.25.24

California Enacts a Suite of New AI and Digital Replica Laws

On September 17, 2024, California Governor Gavin Newsom signed into law two key bills, AB 1836 and AB 2602, aimed at enhancing protections for performers, both deceased and living, in response to the increased adoption of generative artificial intelligence (AI).


09.24.24

Texas Attorney General Settles Deceptive Marketing Allegations Against Health Care AI Company

On September 18, 2024, the Texas Attorney General announced a settlement with Pieces Technologies, a Dallas-based artificial intelligence technology company that markets its software to hospitals and other health care facilities.


09.24.24

U.S. Patent Office Enablement Guidelines in View of Supreme Court Amgen v. Sanofi Decision

The U.S. Patent Office has published updated examination guidelines regarding the enablement requirement in view of the Supreme Court’s May 2023 decision in Amgen v. Sanofi.


09.19.24

Health AI Current “State” - All Eyes on California

Two bills specifically focus on health care and would impose requirements on use of AI by health care providers—including health facilities, clinics, physicians’ offices, or group practices —and health plans, respectively.